Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects

Bruton’s tyrosine kinase (BTK), a pivotal component of B-cell receptor (BCR) signaling, has been recognized as an important driver of the pathogenesis of chronic lymphocytic leukemia. Ibrutinib is a highly active and selectively irreversible inhibitor of BTK, which has been approved to be effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hong, Hu, Pan, Yan, Xiyue, Zhang, Yaping, Shi, Wenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266824/
https://www.ncbi.nlm.nih.gov/pubmed/32581549
http://dx.doi.org/10.2147/OTT.S249586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266824/
https://www.ncbi.nlm.nih.gov/pubmed/32581549
http://dx.doi.org/10.2147/OTT.S249586

Ejemplares similares